

Lise Lafferty, Jake Rance, Carla Treloar, on behalf of the SToP-C Study Group

> AVHEC August 2019



Disclosure of interest: Nothing to declare





Background

- HCV is highly prevalent among the prisoner population; 22% in Australia¹
- A majority of people in prison have injected drugs at least once in their lifetime²
- Current correctional policies prohibit primary prevention measures (e.g., NSP)³
- Pre-treatment interviews showed that HCV was not a priority among injecting networks; injecting events had to be quick so as to not attract attention of officers (limited time for cleaning); some injecting partnerships were based on perceived/confirmed HCV status⁴



 Interviews conducted post-Tx scale-up across 3 male correctional centres

2 maximum security; 1 minimum security

N=23 patients participated

n=20 maximum; n=3 minimum

Sentence length impacted post-Tx availability





Injecting behaviours post-Tx

- Nearly half of participants (n=11) reported injecting drug use since treatment commencement; others reported smoking
- Majority indicated no change in injecting behaviour continued sharing of equipment

Do you think with the new treatments are going to change the way people are injecting together? No. That's not going to change. If anything, it's getting worse (Maximum Security)

· Ongoing issue of scrutiny

Because like I said, especially here, it takes up that extra time to do the bleaching for them to be seen by an officer, so it's just water, water, water (Maximum Security)

· Network safety

I can't speak for other people, but for me, yeah I'd rather use with the fellows that have already done the program [HCV treatment], if they want to use. (Maximum Sec) With the one [needle-syringe] that I use, only two people. (Minimum Security)

• Change in consumption method

Why are you only smoking it rather than injecting? Because there's no needle exchange. (Maximum Sec*)





Discussion

- Minimal change in injecting culture post HCV treatment scale-up
- No other structural or policy changes (treatment is the only change)
- Some injecting networks were formed following treatment on the basis of perceived HCV status
- Prison policies should consider how best to support people who inject drugs to protect themselves against HCV transmission whilst incarcerated





Acknowledgements

This research was supported in part by Gilead Sciences, Inc and a National Health and Medical Research Council (NHMRC) Partnership Project Grant (APP1092547).

We wish to thank the participants for their time and expertise.

The SToP-C Protocol Steering Committee members include:

Stuart Loveday (Hepatitis NSW)	Colette McGrath (JH&FMHN)
Gregory Dore (UNSW Sydney)	Julia Bowman (JH&FMHN)
Andrew Lloyd (UNSW Sydney)	Jason Grebely (UNSW Sydney)
Carla Treloar (UNSW Sydney)	Luke Grant (Corrective Services NSW)
Tony Butler (UNSW Sydney)	Terry Murrell (Corrective Services NSW)
Annabelle Stevens (NSW Health)	Natasha Martin (University of California San Diego)
Georgina Chambers (UNSW Sydney)	Mary Harrod (NSW Users and AIDS Association)
Alison Churchill (Community Restorative Centre)	Marianne Byrne (UNSW Sydney)
Kate Pinnock (Community Restorative Centre)	Sallie Cairnduff (Aboriginal Health & Medical Research Council)

